DelveInsight’s ‘Vasculitis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Vasculitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Vasculitis pipeline domain.
For Vasculitis emerging drugs, the Vasculitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Vasculitis Pipeline Report
- 30+ Vasculitis pipeline therapies are in various stages of development, and their anticipated acceptance in the Vasculitis market would significantly increase market revenue.
- Leading 20+ Vasculitis companies developing novel drug candidates to improve the Vasculitis treatment landscape, including CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and Company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and others.
- Promising Vasculitis pipeline therapies in various stages of development include AMB 301, Research, program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others.
- In October 2021, Novartis Pharmaceuticals initiated a randomized, parallel-group, double-blind, placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of Secukinumab 300 mg administered subcutaneously versus placebo, in combination with glucocorticoid taper regimen, in patients With Giant Cell Arteritis (GCA)
- Chemocentryx has launched TAVNEOS in the fourth quarter of 2021 following FDA approval on October 8, 2021, as an adjunctive treatment in adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids.
- ChemoCentryx received approval from European Union (EU) for its drug, Tavneos (avacopan), to treat adult patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis) in January 2022.
Request a sample and discover the recent breakthroughs happening Vasculitis pipeline landscape in @ Vasculitis Pipeline Report
Vasculitis Overview
Vasculitis involves inflammation of the blood vessels. The inflammation can cause the walls of the blood vessels to thicken, which reduces the width of the passageway through the vessel. If blood flow is restricted, it can damage organs and tissue. Vasculitis can affect people at any age. Some forms affect blood vessels that go to or supply specific organs like your skin, eyes, or brain. Vasculitis symptoms are commonly observed, such as fever, loss of appetite, weight loss, and fatigue.
The most common forms of Vasculitis are Giant cell arteritis, Polymyalgia rheumatica, Polyarteritis nodosa, and Granulomatosis with polyangiitis. Whereas different types of Vasculitis are Large Vessel Vasculitis, Medium Vessel Vasculitis, and Small Vessel Vasculitis. Vasculitis treatment depends on what’s causing your Vasculitis and which organs are affected. Corticosteroid medications, also known as steroids, are generally preferred to fight inflammation.
Vasculitis Pipeline Analysis: Drug Profile
Upadacitinib: AbbVie
AbbVie scientists discovered and developed upadacitinib (RINVOQ). RINVOQ is a JAK inhibitor being researched for use in various immune-mediated inflammatory diseases. RINVOQ inhibited JAK-1 more effectively than JAK-2, JAK-3, and TYK-2 in enzymatic and cellular assays. The importance of inhibiting specific JAK enzymes to therapeutic efficacy and safety is unknown at this time. RINVOQ is currently being studied in phase III trials for rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, giant cell arteritis, and Takayasu arteritis.
Belimumab: GlaxoSmithKline
Belimumab binds to soluble human B lymphocyte stimulator protein (BLyS) and prevents it from binding to B lymphocyte receptors. The binding of BLyS to its receptor is required for B lymphocyte survival. As a result, belimumab suppresses B-cell-mediated immunity and the autoimmune response. It is currently being studied in phase III to treat Anti-neutrophil cytoplasmic antibody-associated Vasculitis.
Vasculitis Pipeline Therapies and Key Companies
- AMB 301: Ambulero
- Research program: Kidney Disorder Therapeutics: Visterra
- BDB 1: Beijing Defengrei Biotechnology
- Vilobelimab: InflaRx
- Guselkumab: Janssen Biotech
- Secukinumab: Novartis
- Upadacitinib: AbbVie
Learn more about the Vasculitis emerging pipeline therapies @ Vasculitis Clinical Trials
Vasculitis Pipeline Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Intravenous
- Inhalation
- Subcutaneous
- By Molecule Type
- Gene therapy
- Stem cell therapy
- Small molecules
Scope of the Vasculitis Pipeline Report
- Coverage: Global
- Key Vasculitis Companies: CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and others.
- Key Vasculitis Pipeline Therapies: AMB 301, Research, program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others.
Dive deep into rich insights for Vasculitis emerging therapies and assessment; visit @ Vasculitis Emerging Therapies
Table of Contents
| 1. | Introduction |
| 2. | Vasculitis Executive Summary |
| 3. | Vasculitis Overview |
| 4. | Vasculitis Pipeline Therapeutics |
| 5. | Vasculitis Pipeline: Late Stage Products (Phase III) |
| 6. | Vasculitis Pipeline: Mid Stage Products (Phase II) |
| 7. | Vasculitis Pipeline: Early Stage Products (Phase I/II) |
| 8. | Vasculitis Pipeline: Preclinical Stage Products |
| 9. | Vasculitis Pipeline: Discovery Stage Products |
| 10. | Vasculitis Pipeline Therapeutic Assessment |
| 11. | Vasculitis Pipeline: Inactive Products |
| 12. | Collaborations Assessment- Licensing / Partnering / Funding |
| 13. | Unmet Needs |
| 14. | Market Drivers and Barriers |
| 15. | Appendix |
| 16. | About DelveInsight |
For further information on the Vasculitis current pipeline therapeutics, reach out @ Vasculitis Therapeutics Assessment
Related Reports
Peripheral Vascular Interventions Market
Peripheral Vascular Interventions Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Peripheral Vascular Interventions companies.
Peripheral Vascular Clot Management Interventions Market
Peripheral Vascular Clot Management Interventions Market Insight, Competitive Landscape, and Market Forecast, 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Peripheral Vascular Clot Management Interventions companies such as Boston Scientific Corporation, Penumbra Inc, Medtronic, Koninklijke Philips N.V., Edward Lifesciences Corporation, among others.
Choroidal Neovascularization Pipeline Insights
“Choroidal Neovascularization Pipeline Insights, 2023” report by DelveInsight outlays comprehensive insights into present clinical development scenario and growth prospects across the Choroidal Neovascularization market. A detailed picture of the Choroidal Neovascularization pipeline landscape is provided, which includes the disease overview, treatment guidelines, and key Choroidal Neovascularization companies involved, such as Johnson & Johnson, Medtronic, Stryker, Terumo Corporation, Penumbra, Inc., Microport Scientific Corporation, Kaneka Corp, and others.
Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market
Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market report delivers an in-depth understanding of Neurovascular Thrombectomy Devices and the historical and forecasted Neurovascular Thrombectomy Devices market trends, market drivers, market barriers, and key Neurovascular Thrombectomy Devices companies involved, such as Stryker, Penumbra, Vesalio, Acandis GmbH, Rapid Medical, Johnson & Johnson, Teleflex Incorporated, Medtronic, NeuroVasc Technologies, Inc., Perflow Medical, Edward LifeSciences Corporation, and many others.
Neurovascular Coiling Assist Devices Market
DelveInsight’s ‘Neurovascular Coiling Assist Devices Market Insights, Competitive Landscape and Market Forecast – 2027’ report delivers an in-depth understanding of Neurovascular Coiling Assist Devices and the historical and forecasted Neurovascular Coiling Assist Devices market trends, market drivers, market barriers, and key Neurovascular Coiling Assist Devices companies involved such as Acandis GmBH, BALT Extrusion, Johnson & Johnson (Cerenovus), Medtronic Plc, Stryker, Terumo (MicroVention), and others.
Peripheral Vascular Clot Management Interventions Market
DelveInsight’s ‘Peripheral Vascular Clot Management Interventions Market Insights, Competitive Landscape, and Market Forecast-2027’ report delivers an in-depth understanding of peripheral vascular clot management interventions and the historical and forecasted peripheral vascular clot management interventions market trends, market drivers, market barriers, and key Peripheral Vascular Clot Management Interventions companies involved such as Boston Scientific Corporation, Penumbra Inc, Medtronic, Koninklijke Philips N.V., Edward Lifesciences Corporation, Cardinal Health, Argon Medical Devices, Inc., Control Medical Technology, B. Braun Melsungen AG., Inari Medical, and others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Hemophilia A Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187